Antipsychotic and Mood Stabilizer Titration Guidelines

Introduction to Titration

The British Journal of Psychiatry recommends a titration schedule for antipsychotics and mood stabilizers with gradual dose increases and widely spaced intervals (14-21 days after initial titration) to minimize side effects while achieving therapeutic benefit 1, 2

The British Journal of Psychiatry suggests starting with low doses of atypical antipsychotics and gradually increasing based on clinical response and tolerability 1, 2
Dose increases for atypical antipsychotics should only occur after adequate trial periods (14-21 days) if response has been inadequate, as recommended by the British Journal of Psychiatry 1, 3
The British Journal of Psychiatry advises avoiding extrapyramidal side effects to encourage medication adherence 2
For risperidone, the initial dose is 2 mg/day, with titration increases only after 14-21 days if response is inadequate, as recommended by the British Journal of Psychiatry 1, 2
The maximum recommended dose for risperidone in first-episode psychosis is 4-6 mg/day, according to the British Journal of Psychiatry 1
Higher doses of risperidone (>6 mg/day) increase the risk of extrapyramidal side effects, as noted in the Annals of Oncology 4

For lithium, the titration goal is to reach therapeutic blood levels (0.6-1.2 mEq/L), with regular serum lithium level checks (target 4-8 mcg/mL), as recommended by the Mayo Clinic Proceedings 5
Lithium requires renal and thyroid function monitoring, according to the Mayo Clinic Proceedings 5
For valproate (divalproex sodium), the initial dose is 125 mg twice daily, with gradual increases to therapeutic blood level (40-90 mcg/mL), as recommended by the Mayo Clinic Proceedings 5
Valproate requires regular liver enzyme tests and platelet counts, according to the Mayo Clinic Proceedings 5

The British Journal of Psychiatry recommends against increasing doses too rapidly, which increases side effect risk, and advises waiting at least 14-21 days between dose increases 1, 2
Failing to monitor for medication-specific adverse effects can lead to poor outcomes, as noted in the Mayo Clinic Proceedings 5
Overlooking physical illnesses that may cause or exacerbate psychiatric symptoms is a common pitfall, according to the British Journal of Psychiatry 2
Using typical antipsychotics as first-line agents is not recommended due to higher rates of extrapyramidal side effects, as advised by the British Journal of Psychiatry 2
If positive symptoms persist after trials of two antipsychotics, the British Journal of Psychiatry suggests reviewing reasons for treatment failure and considering psychosocial strategies alongside medication management 1, 2